Earnings summaries and quarterly performance for Absci.
Executive leadership at Absci.
Board of directors at Absci.
Research analysts who have asked questions during Absci earnings calls.
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
4 questions for ABSI
Also covers: ABCL, ARWR, AZTA +20 more
DC
Debanjana Chatterjee
JonesTrading Institutional Services
4 questions for ABSI
Also covers: CLSD, EYPT, KALV +2 more
Gil Blum
Needham & Company
4 questions for ABSI
Also covers: AUTL, CELC, FATE +9 more
AX
Alexander Xenakis
Truist Securities
3 questions for ABSI
Also covers: CYTK
Arseniy Shabashvili
Guggenheim Securities
3 questions for ABSI
Also covers: TVTX
MG
Morgan Gryga
Morgan Stanley
3 questions for ABSI
Also covers: CERT, HALO, SAGE
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
3 questions for ABSI
Also covers: BSEM, CGEN, CLGN +25 more
GF
George Farmer
Scotiabank
2 questions for ABSI
Also covers: ADAP, INMB, KURA +7 more
SD
Steve Dechert
KeyBanc Capital Markets
2 questions for ABSI
Also covers: ABCL, CERT, LFMD +2 more
SD
Srikripa Devarakonda
Truist Financial Corporation
1 question for ABSI
Also covers: ABCL, AFMD, ARVN +12 more
Vamil Divan
Guggenheim Securities
1 question for ABSI
Also covers: ABBV, ANIP, BHVN +7 more
VP
Vikram Purohit
Morgan Stanley
1 question for ABSI
Also covers: ARGX, ARQT, ASND +11 more
Recent press releases and 8-K filings for ABSI.
Absci Provides Update on ABS-201 Development and Financial Runway
ABSI
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Absci's flagship program, ABS-201, is being developed for androgenetic alopecia (AGA) and endometriosis, utilizing the company's AI engine to develop differentiated assets.
- For AGA, Absci expects safety, tolerability, and PK data in the first half of 2026 and a 13-week interim efficacy readout in the second half of 2026 from its Phase 1/2a HEADLINE trial. A full 26-week readout is anticipated in 2027, with potential approval around 2030.
- The AGA market represents a $25 billion TAM in the US, with registrational studies estimated to cost under $100 million. Absci believes ABS-201 offers a significant advantage over competitors due to its long half-life and high concentration, allowing for fewer doses.
- For endometriosis, Absci plans to start a Phase 2 trial in Q4 2026, with an interim efficacy readout in the second half of 2027.
- Absci reported a balance sheet of approximately $143 million at the beginning of 2026, providing a cash runway into the first half of 2028, which covers the full AGA readout and an interim endometriosis readout.
1 day ago
Absci Provides Update on Clinical Pipeline and Cash Runway
ABSI
New Projects/Investments
Guidance Update
- Absci is advancing its flagship program, ABS-201, for androgenetic alopecia (AGA) and endometriosis.
- Key clinical milestones include H1 2026 for AGA safety/PK data, H2 2026 for AGA 13-week interim efficacy, Q4 2026 for endometriosis Phase 2 initiation, and H2 2027 for both AGA 26-week readout and endometriosis interim efficacy.
- The company reported a balance sheet of approximately $143 million at the beginning of 2026, providing a cash runway into the first half of 2028, which is expected to cover significant clinical readouts.
- Absci aims to partner early-stage assets and anticipates significant OpEx savings in 2026 through the implementation of agentic AI workflows. The US market for AGA is estimated at over $25 billion, with registrational study costs projected to be under $100 million.
1 day ago
Absci Provides Update on ABS-201 Clinical Programs and Financial Runway
ABSI
Product Launch
New Projects/Investments
Guidance Update
- Absci is advancing its flagship program, ABS-201, for androgenetic alopecia (AGA) and endometriosis, utilizing its AI-driven platform to target challenging indications.
- For AGA, the company is targeting a $25 billion US market with a novel subQ injection designed for durable hair growth, with a 13-week interim efficacy readout from its Phase I/IIa trial expected in the second half of 2026. Registrational studies are estimated to cost under $100 million, with potential approval around 2030.
- A Phase II trial for endometriosis is planned to commence in Q4 2026, focusing on pain reduction, with an interim efficacy readout anticipated in the second half of 2027.
- Absci reported a balance sheet of approximately $143 million at the beginning of 2026, providing a cash runway into the first half of 2028, which is expected to cover the full AGA readout and an interim endometriosis readout.
1 day ago
Absci Appoints New Chief Medical Officer and Announces Chief Innovation Officer Retirement
ABSI
Management Change
Hiring
- Absci Corporation appointed Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer to spearhead the clinical development of its expanding AI-designed therapeutics pipeline.
- Dr. Somaratne, formerly Senior Vice President of Clinical Development at Vertex Pharmaceuticals, will enhance the clinical development strategy and execution, including for the flagship ABS-201 program.
- Concurrently, Professor Andreas Busch, Ph.D., Chief Innovation Officer, will retire on March 31, 2026, and will transition to co-chair Absci’s Scientific Advisory Board.
8 days ago
Absci Provides Update on ABS-201 Clinical Development and Strategy
ABSI
New Projects/Investments
Product Launch
- Absci, a clinical-stage AI drug discovery company, is primarily focused on developing its internal pipeline, especially ABS-201.
- The lead asset, ABS-201, targeting androgenic alopecia, has a potential U.S. market opportunity exceeding $25 billion and is anticipated for approval around 2030.
- For androgenic alopecia, ABS-201 is currently in a Phase 1 SAD study with the third cohort dosed and the fourth cohort to be dosed shortly; a 13-week interim readout from the MAD study is expected in H2 2026, with a final 26-week readout in early 2027.
- Absci plans to initiate a Phase 2 study for ABS-201 in endometriosis in Q4 2026.
- The company intends to out-license earlier-stage assets, such as ABS-101 TL1A which is completing its Phase 1 study, to fund its development and focus capital on advancing ABS-201.
Mar 2, 2026, 2:10 PM
Absci Discusses AI Drug Discovery Platform and Pipeline at TD Cowen Conference
ABSI
New Projects/Investments
Product Launch
Guidance Update
- Absci, an AI drug discovery company, highlighted its clinical-stage asset, ABS-201, a prolactin receptor antibody for androgenic alopecia.
- The U.S. market opportunity for ABS-201 in androgenic alopecia is projected to be over $25 billion, with registrational studies estimated at under $100 million and potential approval by 2030.
- A Phase 2 study for ABS-201 in endometriosis is scheduled to commence in Q4 2026.
- Absci is completing a Phase 1 study for 101 TL1A and is actively seeking partners for a novel indication, with a strategy to partner other assets early to fund development.
Mar 2, 2026, 2:10 PM
Absci Highlights ABS-201 Program and AI Platform at Healthcare Conference
ABSI
New Projects/Investments
Product Launch
Guidance Update
- Absci, a clinical-stage AI drug discovery company, is focused on creating valuable assets by leveraging agentic AI for de novo drug design, rather than pursuing a SaaS business model.
- The company's lead asset, ABS-201, a prolactin receptor antibody for androgenic alopecia (AGA), targets a U.S. Total Addressable Market (TAM) that could exceed $25 billion.
- The ABS-201 program is currently in a Phase 1 Single Ascending Dose (SAD) study, with a Multiple Ascending Dose (MAD) study anticipated to provide a 13-week interim readout in H2 2026 and a 26-week final readout in early 2027. Potential approval for AGA is projected around 2030.
- Absci plans to initiate a Phase 2 study for ABS-201 in endometriosis in Q4 2026.
- Management believes there is a significant disconnect between the company's current valuation and the potential of the ABS-201 program, which they expect to close within the next 6 months.
Mar 2, 2026, 2:10 PM
Absci Unveils New AI Model and Provides Clinical Pipeline Updates
ABSI
Product Launch
New Projects/Investments
Guidance Update
- Absci announced the release of its new generative AI model, Origin-1, designed for the de novo creation of antibodies targeting novel, hard-to-drug epitopes.
- The company anticipates two Phase II readouts within the next 24 months for its AI-designed molecules, ABS-101 and ABS-201, targeting androgenic alopecia and endometriosis.
- For ABS-201 in androgenic alopecia, a Phase I/II-A study is underway, with a safety readout expected in the first half of 2026 and a 13-week efficacy readout in the second half of 2026. The U.S. total addressable market for this program is estimated at over $25 billion annually.
- Absci plans to initiate a Phase II trial for ABS-201 in endometriosis in Q4 2026, with a proof-of-concept readout expected a year later.
- As of the end of 2025, Absci's balance sheet held $143 million, providing a cash runway into the first half of 2028.
Jan 14, 2026, 11:45 PM
Absci Announces New AI Model Origin One and Provides Clinical Pipeline Updates
ABSI
Product Launch
New Projects/Investments
Guidance Update
- Absci released its new Origin One AI model for de novo antibody design, enabling targeting of hard-to-drug epitopes and application to its early-stage pipeline.
- The company anticipates a safety readout in H1 2026 and a 13-week efficacy readout in H2 2026 for its ABS-201 androgenic alopecia program, with a Phase 2 proof-of-concept readout for endometriosis expected in Q4 2027.
- As of the end of 2025, Absci's balance sheet stood at $143 million, providing a cash runway into the first half of 2028.
- The estimated total addressable market for ABS-201 in androgenic alopecia is projected to exceed $25 billion annually in the U.S. and $40 billion worldwide.
Jan 14, 2026, 11:45 PM
Absci Presents Pipeline Progress and Financial Outlook at J.P. Morgan Healthcare Conference
ABSI
New Projects/Investments
Product Launch
- Absci reported a balance sheet of over $143 million as of December 31, 2025, providing a runway into the first half of 2028.
- The company is advancing three clinical-stage programs, including ABS-201 for Androgenetic Alopecia (AGA) and Endometriosis, and ABS-101 for Inflammatory Bowel Disease (IBD).
- Key catalysts for ABS-201 in AGA include PK and interim safety readouts expected in 1H 2026, with an interim Proof-of-Concept (PoC) readout anticipated in 2H 2026. Phase 2 initiation for ABS-201 in Endometriosis is also expected in 2H 2026.
- ABS-201 for Endometriosis has the potential to generate over $4.5 billion in peak sales.
Jan 14, 2026, 11:45 PM
Quarterly earnings call transcripts for Absci.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more